Cagrilintide vs Octreotide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Octreotide
Octreotide (Sandostatin) is a synthetic somatostatin analog FDA-approved for acromegaly, carcinoid tumors, and VIPomas. It inhibits growth hormone and various GI hormones.
Full details →Side-by-Side Comparison
| Aspect | Cagrilintide | Octreotide |
|---|---|---|
| Mechanism | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. | Binds to somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit GH, glucagon, insulin, and gastric secretions. Reduces blood flow to GI tract and inhibits tumor hormone secretion. |
| Typical Dosage | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. | Varies by indication. Acromegaly: 50-100mcg three times daily initially, up to 500mcg TID. LAR (long-acting): 20-30mg IM every 4 weeks. |
| Administration | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. | Subcutaneous injection for immediate-release (between meals). Intramuscular for LAR depot form. Requires monitoring of gallbladder, glucose, and thyroid. |
| Side Effects | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. | GI effects (diarrhea, nausea, abdominal pain), gallstones (up to 25% of long-term users), injection site reactions, and blood glucose changes. |
| Best For |